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1. Introduction 
In human pregnancy a number of C2102 steroid 
mono- and disulphates appear in plasma nd attain 
total concentrations a high as 10/ag/ml (about 30/IM) 
in the last trimester [1,2]. A C2103 steroid monosul- 
phate is also present and has been characterized as
5a-pregnane-3cz,20a,21-triol 3-su phate [3]. This com- 
pound seems to occur only in pregnant women and in 
the newborn infant [4-6] .  Although the C2102 
steroids are almost certainly metabolites of proges- 
terone, the precursor of 5c~-pregnane-3ct,20a,21-triol 
monosulphate is unknown. During a study of the 
metabolism of deuterium-labelled 3a-hydroxy-5et- 
pregnan-20-one sulphate in pregnant women, deuterium 
was found to be incorporated into this triol. Further- 
more, the rate of labelling indicated that sulphated 
5ct-pregnane-3a,20a,21-triol in pregnancy plasma 
derives olely from 3ct-hydroxy-5ct-pregnan-20-one 
sulphate. 
2. Materials and methods 
3/3-Hydroxy-5ct-[3a,11,11-2H a ] pregnan-20-one 
[7] was epimerized at C-3, without appreciable oss 
of deuterium [8], by the two-step sequence described 
by Bose et al. [9]. This gave 3ct-hydroxy-5a- [3/3,11,11- 
2H3] pregnan-20-one, whose isotopic purity was 
84.5%, as determined by mass spectrometry. 
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The labelled pregnanolone was transformed into its 
sulphate according to the method of Mumma [10] 
and the product purified by chromatography on a 
column of Sephadex LH-20, with chloroform/methanol 
(1:1, v/v), saturated with KC1, as the eluting solvent 
[ 11 ]. The resulting potassium steroid sulphate was 
stored at 5°C in 50% aqueous ethanol, containing a
trace of KOH, at a concentration of 3.8 mM. 
Aliquots of the above stock solution corresponding 
to about 6 #mol of the steroid were made up to 10 ml 
with isotonic glucose solution. Following sterilization, 
these solutions were injected intravenously into three 
healthy women in the last trimester of pregnancy. 
Immediately prior to the injection, and at six intervals 
over a period of 15-24 h, a blood sample (20 ml) was 
withdrawn into a heparinized tube which was imme- 
diately centrifuged. The plasma samples were stored 
at -18°C until analyzed. 
Steroid mono- and disulphates were extracted from 
plasma nd separated by chromatography on Sephadex 
LH-20 [2,12]. Following solvolysis, the steroids from 
the monosulphate fraction were separated by chroma- 
tography on Lipidex®-5000 (Packard International 
SA, Ziirich) using the solvent system hexane/chloro- 
form/methanol, 85:15:1 (by vol), into mono-, di- and 
trihydroxy fractions [13]. Steroids in these fractions 
were analyzed, as their trimethylsilyl ether derivatives, 
by gas chromatography-mass spectrometry. An LKB 
9000 instrument was used, equipped with glass 
columns (3.5 m X 3 mm i.d.) packed with 1.5% 
HiEff 8 BP on Gas Chrom Q or 1.5% SE-30 on 
Chromosorb W HP. Repetitive magnetic scanning was 
employed [14] and the data were recorded on mag- 
netic tape and evaluated off-line on an IBM 1800 
computer [14,15]. The deuterium excess of 3a- 
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hydroxy-5t~-pregnan-20-one, 5a-pregnane-3a,20~-diol 
and 5a-pregnane-3c~,20a,21-triol was determined by 
comparison of appropriate ions (m/e 390 (M+), m/e 
269 (M-15-2×90) and m/e 449 (M-103), respectively) 
in averaged spectra of the trimethylsilyl ether deriva- 
tives of the unlabelled and labelled compounds in
samples taken before and after injection of the 
deuterated pregnanolone sulphate. All samples were 
analyzed under identical conditions. 
3. Results 
Following injection of 3a-hydroxy-5a- [3/3,11,11- 
2H3] pregnan-20-one sulphate, deuterium appeared 
in the monosulphates of 5c~-pregnane-3a,20c~-diol and 
5ct-pregnane-3~,20~,21-triol. Only molecules with 
zero or three deuterium atoms were found (after 
correction for isotopic impurity of the injected com- 
pound) indicating that all deuterium labels remained 
bound to the steroid skeleton. The rate of disappear- 
ance from plasma of the injected steroid and the rate 
of formation and decay of trideuterated species of 
the above diol and triol monosulphates in one of the 
subjects are shown in rigA. Similar semi-log plots were 
obtained for the other subjects. The decay function 
for the [2H3 ] pregnanolone sulphate could be resolved 
by a curve-peeling procedure into two exponential 
components with half-life times of about 0.9 and 4 h, 
respectively. The 20-keto group was rapidly reduced 
and the 5a-pregnane-3a,2Oa-diol 3-sulphate formed 
also had a half-life time of 4 h. The terminal segment 
of the decay curve for 5a-pregnane-3c~,20ct,21-triol 
monosulphate gave a half-life time for this steroid of 
about 5 h. The functions for disappearance of labelled 
pregnanediol monosulphate and the injected precursor 
intersected the function for labelled 5a-pregnane- 
3a,20a,21-triol monosulphate close to its maximum 
(about 1 h after injection). This indicates that the 
injected compound served as the exclusive precursor 
of the latter steroid. Estimates of production rates of 
the pregnanolone/pregnanediol couple and of the 
pregnanetriol gave values of about 125/2mol/d and 
25/amol/d, respectively. A detailed kinetic study of 
these and related steroid sulphates i in progress. 
4. Discussion 
This study has shown that 3ct-hydroxy-5a-pregnan- 
20-one sulphate is the sole precursor of 5a-pregnane- 
3a,20a,21-triol sulphate in pregnant women. It cannot 
be established from the available data whether the 
injected compound was hydroxylated atC-21 prior 
to reduction of the 20-keto group. However, this 
hydroxylation may be analogous to the 16a-hydroxy- 
lation in pregnant women of 3/~-hydroxy-5a-pregnan- 
20-one sulphate and the corresponding 20a-hvdroxy- 
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Fig.1. Semilogarithmic plots of deuterium excess vs time of steroids in plasma of a pregnant woman injected with 3a-hydroxy- 
5a-3#,11,11-2H~ pregnan-20-one sulphate: (~)3a-hydroxy-5a-pregnan-20-one sulphate; (~) 5a-pregnane-3a,20c~-diol 3-sulphate; 
(o) 5a-pregnane-3~,20a,21-triol 3-su phate. 
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steroid [16], where both the precursors and the 16a- 
hydroxylated metabolites undergo continuous 
oxidoreduction at C-20. Sulphates of  C2103 steroids 
possessing a 20-keto-21-hydroxy structure are present 
in urine during pregnancy [17,18] and oxidoreduction 
at C-20 of these steroids is therefore likely to occur. 
Loss of deuterium from the 3/3 position of the 
injected steroid sulphate and of its metabolites was 
not observed. This indicates that hydrolysis, oxido- 
reduction and resulphation at C-3 did not occur. 
Indirectly, it supports the contention that the sulphate 
ester at C-3 remained intact since a free hydroxyl 
group at C-3 in all probability would undergo xido- 
reduction with concomitant loss of deuterium, as is 
the case in the rat [19]. Thus, one may conclude 
that the intact steroid sulphate served as substrate for 
the 21-hydroxylase. 
Hydroxylation at C-21 of a steroid sulphate has 
not been described previously. However, C21 sterpid 
sulphates are known to be hydroxylated in several 
other positions in fetal organs, see [20,21 ]. More 
recently, microsomal preparations from liver of adults 
have been found to catalyze hydroxylations of 3/3- 
hydroxy-5-pregnen-20-one sulphate [22]. Although 
the fetal liver has a high capacity for 21-hydroxyla- 
tion of steroids [23], this organ is unlikely to be the 
site of formation of 5a-pregnane-3a,20a,21-triol 
monosulphate in maternal plasma, since transplacental 
passage of a 3-sulphate would probably be accom- 
panied by hydrolysis [20] and oxidoreduction. 
Furthermore, 5a-pregnane-3a,20a,21-triol mono- 
sulphate has been shown to be present in maternal 
plasma in two cases of intrauterine fetal death [2]. 
This evidence, coupled with the present findings, 
strongly points to the maternal compartment as the 
site of 21-hydroxylation f sulphated, saturated 
progesterone metabolites. This conclusion does not 
exclude the formation of other isomers of pregnane- 
3,20,21-triol from 21-hydroxylated precursors such 
as 21-hydroxy-4-pregnene-3,20-dione [24]. 
Sulphates of pregnane-3,20,21-triols have only been 
found in biological fluids from pregnant women [6] 
and from newborn infants [6,25]. Our findings 
indicate that 21-hydroxylation of sulphated C2102 
steroids is an important metabolic pathway in preg- 
nancy. A steroid sulphate-specific 21-hydroxylase 
would account for the elevated levels of 5a-pregnane- 
3a,20a,21-triol monosulphate in women with 
intrahepatic cholestasis, where the precursor is 
present in abnormally high concentrations [26]. 
Furthermore, the presence of such an enzyme system 
possibly located in the liver, might also explain the 
finding of normal amounts of 3/3,21-dihydroxy-5- 
pregnen-20-one and 5-pregnene-3/3,20a,21-triol 
disulphates in infants with an adrenal 21-hydroxylase 
deficiency [27]. 
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